home
Author : adminDate : 2020-10-21 18:00

Rivoceranib gets the 'Approval for Therapeutic Use' for Terminal Gastric Cancer Patients

HLB Life Science, which holds the copyright of Rivoceranib in Korea, has been approved by the Registry of Food and Drug Safety (MFDS) for the use of clinical trial medicines as a treatment at Korean medical sites, apart from the approval process for new drugs.

 

On the 21st, MFDS registered Rivoceranib in the 'approval for therapeutic use' status of the integrated drug information system. This allows Rivoceranib to be prescribed at a licensed hospital for the treatment of terminal gastric cancer patients. The ‘approval for therapeutic use’ status is a system that authorizes life-threatening patients to use drugs at the development stage, which allows terminal gastric cancer patients to choose Rivoceranib as a new treatment option.

 

HLB ended the third phase of global clinical trials for terminal gastric cancer patients conducted at 88 general hospitals in 12 countries around the world in June last year and is currently preparing to apply for a marketing permit. In addition, the company is conducting global clinical trials on various indications such as liver cancer, Adenoid Cystic Carcinoma (ACC), and colon cancer.

 

An HLB official said, "We are very pleased that the following approval will open the way for patients suffering from lack of alternative treatments to be prescribed Rivoceranib," and added, "with using the strengths as an oral drug with fewer side effects, we expect Rivoceranib to raise the quality of the patients’ lives."